The 4 most recent market catalysts affecting $XAIR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 55
Beyond Air New US Patent App #20260284331 Published Today For "METHODS EMPLOYING GASEOUS NITRIC OXIDE FOR INHIBITING TUMOR GROWTH".
Beyond Air (XAIR) has published a new US patent application (US-20260284331-A1) related to the use of gaseous nitric oxide for inhibiting tumor growth. This is a positive developme…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 65
Lake Street Initiates Coverage On Beyond Air with Buy Rating, Announces Price Target of $10
Lake Street analyst Frank Takkinen has initiated coverage on Beyond Air (XAIR), assigning a 'Buy' rating and a $10 price target. This event is significant because new analyst cover…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 85
Beyond Air shares are trading higher after the FDA granted the company Breakthrough Device Designation to LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease
This FDA Breakthrough Device Designation is a major positive catalyst for Beyond Air, as it expedites the regulatory review process and offers potential for priority review and enh…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 75
Beyond Air Affirms FY2027 Sales Guidance of $16.000M-$18.000M vs $9.137M Est
Beyond Air (XAIR) has affirmed its FY2027 sales guidance, keeping it at $16.000 million-$18.000 million. This is a crucial development because the reaffirmed guidance is substantia…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.